Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

revumenib (SNDX-5613)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Syndax Pharma

Drug class:

Menin-MLL inhibitor

Related drugs:

‹

›

NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B	SNDX-5613 Sensitive: B - Late Trials SNDX-5613 Sensitive : B
MLL rearrangement	Leukemia	MLL rearrangement	Leukemia	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2
NPM1 mutation	Leukemia	NPM1 mutation	Leukemia	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2	SNDX-5613 Sensitive: C2 – Inclusion Criteria SNDX-5613 Sensitive : C2
KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	KMT2A rearrangement + NPM1 mutation	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: C3 – Early Trials SNDX-5613 Sensitive : C3	SNDX-5613 Sensitive: C3 – Early Trials SNDX-5613 Sensitive : C3
NUP98 rearrangement	Acute Myelogenous Leukemia	NUP98 rearrangement	Acute Myelogenous Leukemia	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3	venetoclax + SNDX-5613 Sensitive: C3 – Early Trials venetoclax + SNDX-5613 Sensitive : C3
NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D
NPM1 expression	Acute Myelogenous Leukemia	NPM1 expression	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D
KMT2A expression	Acute Myelogenous Leukemia	KMT2A expression	Acute Myelogenous Leukemia	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D	SNDX-5613 Sensitive: D – Preclinical SNDX-5613 Sensitive : D
KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	KMT2A rearrangement + RAS mutation	B Acute Lymphoblastic Leukemia	selumetinib + SNDX-5613 Sensitive: D – Preclinical selumetinib + SNDX-5613 Sensitive : D	selumetinib + SNDX-5613 Sensitive: D – Preclinical selumetinib + SNDX-5613 Sensitive : D
KMT2A rearrangement + RAS mutation	Acute Myelogenous Leukemia	KMT2A rearrangement + RAS mutation	Acute Myelogenous Leukemia	selumetinib + SNDX-5613 Sensitive: D – Preclinical selumetinib + SNDX-5613 Sensitive : D	selumetinib + SNDX-5613 Sensitive: D – Preclinical selumetinib + SNDX-5613 Sensitive : D
FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + NPM1 mutation	Acute Myelogenous Leukemia	SNDX-5613 + FHD-286 Sensitive: D – Preclinical SNDX-5613 + FHD-286 Sensitive : D	SNDX-5613 + FHD-286 Sensitive: D – Preclinical SNDX-5613 + FHD-286 Sensitive : D
MLL-AF4 fusion	Acute Myelogenous Leukemia	MLL-AF4 fusion	Acute Myelogenous Leukemia	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D	SNDX-5613 + ORY-1001 Sensitive: D – Preclinical SNDX-5613 + ORY-1001 Sensitive : D